Encompass Health Executive Compensation (FY25)
EHC · Birmingham, AL · Executive and director compensation, fiscal 2022 to 2025
The Encompass Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 12, 2026Latest filing (8-K): May 11, 2026
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
349 figures on this page: 340 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Mark Tarr: $9,301,929 → $10,297,258 (10.7% higher)
Say-on-pay support: 97.6% → 96.5% (1.1 points lower)
CEO pay ratio: 204:1 → 203:1 (0.5% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Encompass Health's chief executive and what were they paid?
Mark Tarr was paid $10,297,258 in total compensation as President and Chief Executive Officer for fiscal 2025. Tarr's total was 10.7% higher than the $9,301,929 reported for fiscal 2024.
What was Encompass Health's say-on-pay result?
The say-on-pay proposal drew 96.5% of votes cast for or against in favor at the meeting held May 7, 2026 for fiscal 2025.
Which companies are in Encompass Health's peer group?
The disclosed peer group names Acadia Healthcare, Agilon health, Alignment Healthcare, Amedisys and AMN Healthcare, among others.
What is Encompass Health's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 203:1, against median employee compensation of $50,647.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Tarr President and Chief Executive Officer President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Douglas Coltharp Executive Vice President and Chief Financial Officer Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Patrick Darby Executive Vice President General Counsel and Secretary Executive Vice President General Counsel and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Elissa Charbonneau Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Price Chief Accounting Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Tarr President and Chief Executive Officer President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Douglas Coltharp Executive Vice President and Chief Financial Officer Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Patrick Darby Executive Vice President General Counsel and Secretary Executive Vice President General Counsel and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Elissa Charbonneau Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Price Chief Accounting Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Tarr President and Chief Executive Officer President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Douglas Coltharp Executive Vice President and Chief Financial Officer Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Patrick Darby Executive Vice President General Counsel and Secretary Executive Vice President General Counsel and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Elissa Charbonneau J. Charbonneau Chief Medical Officer Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Price Chief Accounting Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Tarr President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Douglas Coltharp Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Patrick Tuer Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Patrick Darby Executive Vice President, General Counsel and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Elissa Charbonneau Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Douglas E. Coltharp | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Douglas E. Coltharp | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Douglas E. Coltharp | OTHER | ◇ | — | — | ◇ | — | — | ◇ |
| Elissa J. Charbonneau | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Elissa J. Charbonneau | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Mark J. Tarr | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Mark J. Tarr | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Mark J. Tarr | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Patrick Darby | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Patrick Darby | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Patrick Darby | OTHER | ◇ | — | — | ◇ | — | — | ◇ |
| Patrick W. Tuer | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Patrick W. Tuer | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Patrick W. Tuer | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Douglas Coltharp | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Elissa Charbonneau | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Patrick Tuer | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Mark Tarr | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Patrick Darby | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Exercise Price | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Douglas Coltharp
Executive Vice President and Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance cash amount | ◇ |
| Equity acceleration on change in control | ◇ |
Elissa Charbonneau
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance cash amount | ◇ |
| Equity acceleration on change in control | ◇ |
Mark Tarr
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance cash amount | ◇ |
| Equity acceleration on change in control | ◇ |
| Excise tax treatment | ◇ |
Patrick Darby
Executive Vice President, General Counsel and Secretary · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance cash amount | ◇ |
| Equity acceleration on change in control | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Greg D. Carmichael Board chair | ◇ | ◇ | — | — | — | ◇ | ◇ |
Leslye G. Katz | ◇ | ◇ | — | — | — | ◇ | ◇ |
Christopher R. Reidy | ◇ | ◇ | — | — | — | ◇ | ◇ |
Nancy M. Schlichting | ◇ | ◇ | — | — | — | ◇ | ◇ |
Joan E. Herman | ◇ | ◇ | — | — | — | ◇ | ◇ |
Kevin J. O'Connor | ◇ | ◇ | — | — | — | ◇ | ◇ |
Terrance Williams | ◇ | ◇ | — | — | — | ◇ | ◇ |
Edward M. Christie III | ◇ | ◇ | — | — | — | ◇ | ◇ |
Patricia A. Maryland | ◇ | ◇ | — | — | — | ◇ | ◇ |
Cain A. Hayes and Mark J. Tarr served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Acadia Healthcare ACHC
- Agilon health AGL
- Alignment Healthcare ALHC
- Amedisys AMED
- AMN Healthcare AMN
- BrightSpring Health Services BTSG
- Brookdale Senior Living BKD
- Chemed CHE
- Community Health Systems CYH
- DaVita DVA
- Ensign Group ENSG
- Labcorp Holdings LH
- ModivCare MODV
- Option Care Health OPCH
- PACS Group PACS
- Quest Diagnostics DGX
- R1 RCM RCM
- Select Medical Holdings SEM
- Surgery Partners SGRY
- Universal Health Services UHS
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 7, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 1, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 2, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 4, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 5, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 6, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 6, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 3, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 3, 2018 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Encompass Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Encompass Health sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
349 figures on this page: 340 cited to the filing that reported them, 9 calculated from figures it prints.
340 cited to the filing
9 calculated from the filing
Documents cited
- 0000785161-26-000151
- 0000785161-26-000105CEO Pay Ratio · Compensation of Directors · Director Compensation · Grants of Plan-Based Awards During 2025 · and 3 more sections
- 0000785161-25-000025
- 0000785161-25-000013Compensation Discussion and Analysis · Summary Compensation Table
- 0000785161-24-000031Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000785161-24-000020Summary Compensation Table
- 0000785161-23-000034Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000785161-23-000024Summary Compensation Table
- 0000785161-22-000024
- 0000785161-21-000027
- 0000785161-20-000036
- 0000785161-19-000027
- 0000785161-18-000032
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Encompass Health executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/EHC (accessed 2026).
Short form: data: Velarion
The Encompass Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Encompass Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Encompass Health discloses
The companies named in EHC's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}